Scientists Transform Beating Heart Stem Cells Into Brain Cells

Jumping to a New Fate

Stem cells are kind of a blank slate. They’re “pluripotent,” meaning that they can transform into any type of cell in the body. There are a series of steps involved in this transformation process, called canalization. Until now, it was thought that once stem cells start undergoing canalization, they can’t change course to become other, different cell types.

But Saucerman’s collaborators at the Gladstone Institutes in San Francisco, led by Benoit G. Bruneau, used CRISPR genome-editing approaches to turn off the Brm gene in mouse stem cells undergoing canalization into heart cells. This resulted in the mouse cells lacking a protein called Brahma.

Turning off Brm prevented stem cells from becoming beating heart cells. Additionally, they had switched from being heart precursors to become precursors for brain cells.

Collaboration Yields Groundbreaking Data

“This study was the first to explore the effect of Brahma on cardiac differentiation,” said Ali Khalilimeybodi, a researcher on Saucerman’s team who developed the computer model used to guide the research. “And by using the computational models, we get a deeper understanding of the mechanism, that Brahma can coerce changes in the cell fate, or differentiation, process.”

Saucerman emphasized the somewhat unconventional approach of supporting real-world experimentation with computer model data.

“In this case, they had already done a lot of experiments,” he said. “We went back and forth a lot, including [over] more and more of the data.”

This process helped refine the model for better predictions and guidance, he added. “The model really highlights this irreversible biochemical switch. If you disrupt this switch, a stem cell takes a detour down the brain route. The modeling provides a mathematical explanation for this developmental process.”

The research challenges fundamental ideas about how stem cells progress to mature body cells. More research will paint a fuller picture, which could lead to the development of new treatments for a number of conditions.

“There’s an awful lot to be explored on what happens after – how do these cells become mature, highly contractile cells?” Saucerman said. “I think that’s a major challenge for the field. That has therapeutic implications, because we need to be able to develop mature cells to then transplant into patients or to discover new drugs.”

Findings Published

The researchers published their findings in the scientific journal Nature. The research team consisted of Swetansu K. Hota, Kavitha S. Rao, Andrew P. Blair, Ali Khalilimeybodi, Kevin M. Hu, Reuben Thomas, Kevin So, Vasumathi Kameswaran, Jiewei Xu, Benjamin J. Polacco, Ravi V. Desai, Nilanjana Chatterjee, Austin Hsu, Jonathon M. Muncie, Aaron M. Blotnick, Sarah A. B. Winchester, Leor S. Weinberger, Ruth Hüttenhain, Irfan S. Kathiriya, Nevan J. Krogan, Jeffrey J. Saucerman and Benoit G. Bruneau.

The work was funded by the National Institutes of Health (grants P01HL089707, P01HL146366, UM1HL098179, R01HL114948, R01HL137755, 2T32- HL007731 26, C06 RR018928), the American Heart Association (grant 13POST17290043 and Career Development Award 861914), the Tobacco Related Disease Research Program (grant 22FT-0079), the Society for Pediatric Anesthesia, the Hellman Family Fund, a UCSF REAC Award and the UCSF Department of Anesthesia and Perioperative Care.

UVA’s Department of Biomedical Engineering is a joint program of the School of Medicine and the School of Engineering.

To keep up with the latest medical research news from UVA, subscribe to the Making of Medicine blog.